Optiscan Imaging Ltd (ASX: OIL) is a global leader in the development, manufacture and commercialisation of endomicroscopic digital imaging technology solutions
Delighted to be collaborating with Design Industry in developing our new product portfolio. With 260 industry awards over 35 years, we look forward to perfecting our new devices for clinicians, health systems and patients.
#imaginethepossibilities#digitalpathology
Optiscan Imaging Ltd wishes all our US colleagues, clinicians, partners, friends, and their families a wonderful #Thanksgiving.
We hope your day is filled with warmth, happiness, and the company of those closest to you.
Delighted to welcome Brendan Fafiani as our new Chief Operating Officer. Mr Fafiani will lead operations at our Melbourne headquarters, our operational planning, commercialisation strategy, customer and development efforts.
Read: optiscan.com/investor/asx-an…#optiscanimaging#ASX
Pleased to announce interim readout on our Breast Cancer Intraoperative Assessment Study, revealing excellent correlation between our real-time #CLE imaging and traditional histological analysis.
Read more: lnkd.in/gXYQ8uf2#optiscanimaging#digitalpathology#asx
Optiscan Imaging has rounded out a dynamic year with a whopping 66 per cent revenue boost to nearly $1.7 million following the sale of its ViewnVivo research device to an American pharmaceutical company. #BULLSNBEARSWAbit.ly/3PlkSl9
We have released our Annual Report FY23, with revenues increasing to $1.68m ( 66%) and net cash outflows decreasing from $3.8m to $3.2m. We thank all our collaborators, shareholders, and employees for their ongoing support & look forward to FY24.
optiscan.com/investor/asx-an…
Optiscan Imaging has been invited to present its remarkable confocal endomicroscopic medical imaging technology at two key international conferences in North and South America.
#BULLSNBEARSWAbit.ly/3XQk8Hy
We are pleased to advise a study from our clinical research partnership with the Melbourne Dental School has been published in Fontiers in Oncology this week.
Read the paper below frontiersin.org/journals/onc…